Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Hold” by Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Rating) has earned an average rating of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.63.

ESPR has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of Esperion Therapeutics from $5.00 to $7.00 and gave the stock an “underweight” rating in a report on Friday, July 15th. Credit Suisse Group cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $7.00 to $6.00 in a report on Wednesday, August 3rd. Finally, Cowen dropped their price target on shares of Esperion Therapeutics to $13.00 in a research report on Tuesday, August 9th.

Insider Activity

In other Esperion Therapeutics news, CEO Sheldon L. Koenig purchased 8,606 shares of the stock in a transaction that occurred on Friday, August 5th. The shares were acquired at an average cost of $5.80 per share, with a total value of $49,914.80. Following the completion of the transaction, the chief executive officer now owns 198,771 shares in the company, valued at $1,152,871.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Esperion Therapeutics news, CEO Sheldon L. Koenig purchased 8,606 shares of the stock in a transaction that occurred on Friday, August 5th. The shares were acquired at an average cost of $5.80 per share, with a total value of $49,914.80. Following the completion of the transaction, the chief executive officer now owns 198,771 shares in the company, valued at $1,152,871.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joanne M. Foody sold 3,901 shares of the stock in a transaction dated Tuesday, July 19th. The stock was sold at an average price of $6.55, for a total transaction of $25,551.55. Following the sale, the insider now owns 109,077 shares in the company, valued at $714,454.35. The disclosure for this sale can be found here. Insiders have sold 7,749 shares of company stock valued at $52,228 over the last ninety days. 3.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $25,000,000. Denali Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the 1st quarter valued at approximately $49,000. Ensign Peak Advisors Inc acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $666,000. Rafferty Asset Management LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $172,000. Finally, Wasatch Advisors Inc. boosted its position in Esperion Therapeutics by 95.0% during the 4th quarter. Wasatch Advisors Inc. now owns 6,386,263 shares of the biopharmaceutical company’s stock worth $31,931,000 after buying an additional 3,111,903 shares during the period. 94.63% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Down 2.1 %

Esperion Therapeutics stock opened at $6.96 on Friday. The stock has a market capitalization of $463.20 million, a PE ratio of -1.09 and a beta of 0.17. Esperion Therapeutics has a twelve month low of $3.28 and a twelve month high of $13.14. The company has a 50 day moving average of $6.93 and a 200-day moving average of $6.07.

Esperion Therapeutics (NASDAQ:ESPRGet Rating) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.10). The company had revenue of $18.80 million for the quarter, compared to analyst estimates of $18.62 million. During the same period last year, the firm earned ($1.67) EPS. The company’s revenue was down 53.8% compared to the same quarter last year. Equities analysts anticipate that Esperion Therapeutics will post -3.81 EPS for the current fiscal year.

About Esperion Therapeutics

(Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Recommended Stories

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.